SARS-COV-2 Spike RBD PaB
To Order Contact us: [email protected]
SARS-CoV-2 Spike RBD Rabbit pAb |
|||
| MBS9143560-02mL | MyBiosource | 0.2mL | EUR 545 |
SARS-CoV-2 Spike RBD Rabbit pAb |
|||
| MBS9143560-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| A20606 | Abclonal | 20μL | EUR 623.48 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| E45R29006N | EnoGene | 50 ul | EUR 297.75 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| MBS9143749-002mL | MyBiosource | 0.02mL | EUR 200 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| MBS9143749-005mL | MyBiosource | 0.05mL | EUR 255 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| MBS9143749-01mL | MyBiosource | 0.1mL | EUR 345 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| MBS9143749-02mL | MyBiosource | 0.2mL | EUR 545 |
SARS-CoV Spike RBD Rabbit pAb |
|||
| MBS9143749-5x02mL | MyBiosource | 5x0.2mL | EUR 2265 |
SARS CoV 2 Spike RBD, mFc/His tag |
|||
| E2S209905P | EnoGene | 100ul | EUR 595 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
SARS-COV-2 Spike RBD(Omicron) Protein pAb |
|||
| A21926 | Abclonal | 500μL | EUR 60.22 |
SARS-COV-2 Spike RBD (Omicron) Protein pAb |
|||
| MBS9145378-002mL | MyBiosource | 0.02mL | EUR 220 |
SARS-COV-2 Spike RBD (Omicron) Protein pAb |
|||
| MBS9145378-005mL | MyBiosource | 0.05mL | EUR 295 |
SARS-COV-2 Spike RBD (Omicron) Protein pAb |
|||
| MBS9145378-01mL | MyBiosource | 0.1mL | EUR 430 |
SARS-COV-2 Spike RBD (Omicron) Protein pAb |
|||
| MBS9145378-02mL | MyBiosource | 0.2mL | EUR 600 |
SARS-COV-2 Spike RBD (Omicron) Protein pAb |
|||
| MBS9145378-5x02mL | MyBiosource | 5x0.2mL | EUR 2525 |
SARS-CoV-2 Spike-1 RBD |
|||
| MBS692572-0025mg | MyBiosource | 0.025mg | EUR 380 |
SARS-CoV-2 Spike-1 RBD |
|||
| MBS692572-5x0025mg | MyBiosource | 5x0.025mg | EUR 1410 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| A73680 | EpiGentek |
|
|
SARS-CoV-2 Spike RBD Nanobody |
|||
| CSB-RA33245A2GMY-100ul | Cusabio | 100ul | EUR 700 |
|
Description: GICA In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good. |
|||
SARS-CoV-2 Spike RBD Nanobody |
|||
| CSB-RA33245A2GMY-50ul | Cusabio | 50ul | EUR 420 |
|
Description: GICA In the Colloidal Gold Immunochromatography Assay detection system, the background of antibody (CSB-RA33245A2GMY) is clean, the detection limit can be as low as 25ng/ml (1.75ng/0.07ml), and the sensitivity is very good. |
|||
SARS-CoV-2 Spike RBD Antibody |
|||
| E40P12575 | EnoGene | N/A | EUR 346.5 |
|
Description: N/A |
|||
SARS-CoV-2 Spike RBD Nanobody |
|||
| MBS5316567-01mL | MyBiosource | 0.1mL | EUR 1080 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| MBS5316567-5x01mL | MyBiosource | 5x0.1mL | EUR 4710 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| MBS7136646-005mL | MyBiosource | 0.05mL | EUR 355 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| MBS7136646-01mL | MyBiosource | 0.1mL | EUR 560 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| MBS7136646-5x01mL | MyBiosource | 5x0.1mL | EUR 2510 |
SARS-CoV-2 Spike RBD Nanobody |
|||
| 10-2874 | Fitzgerald Industries International | 100 ul | Ask for price |
Recombinant SARS-CoV-2 Spike RBD |
|||
| AP60510 | SAB | each | Ask for price |
Recombinant SARS-CoV-2 Spike RBD |
|||
| P1595-.1 | ApexBio | 100ug | EUR 647.2 |
|
Description: Peptides & Proteins|Recombinant Proteins |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
|||
| 9087-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
|||
| 9087-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
|||
| MBS154650-01mg | MyBiosource | 0.1mg | EUR 500 |
SARS-CoV-2 (COVID-19) Spike RBD Antibody |
|||
| MBS154650-5x01mg | MyBiosource | 5x0.1mg | EUR 2230 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620023-1mg | Abbexa | 1 mg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620023-5mg | Abbexa | 5 mg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620024-100g | Abbexa | 100 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620024-200g | Abbexa | 200 µg | EUR 1700 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620024-50g | Abbexa | 50 µg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620066-100g | Abbexa | 100 µg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620066-1mg | Abbexa | 1 mg | EUR 1700 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620066-200g | Abbexa | 200 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620071-100g | Abbexa | 100 µg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620071-1mg | Abbexa | 1 mg | EUR 1700 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620071-200g | Abbexa | 200 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620075-100g | Abbexa | 100 µg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620075-1mg | Abbexa | 1 mg | EUR 1700 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620075-200g | Abbexa | 200 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620090-100g | Abbexa | 100 µg | EUR 287.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620090-1mg | Abbexa | 1 mg | EUR 1700 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620090-200g | Abbexa | 200 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620094-100g | Abbexa | 100 µg | EUR 412.5 |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620094-1mg | Abbexa | 1 mg | Ask for price |
SARS-CoV-2 Spike Protein RBD |
|||
| abx620094-200g | Abbexa | 200 µg | EUR 1300 |
SARS CoV 2 Spike Protein (RBD), His tag, E.coli |
|||
| E2S209916P | EnoGene | 100ul | EUR 595 |
|
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
|||
SARS-CoV Spike Protein RBD |
|||
| MBS515782-001mg | MyBiosource | 0.01mg | EUR 225 |
SARS-CoV Spike Protein RBD |
|||
| MBS515782-002mg | MyBiosource | 0.02mg | EUR 290 |
SARS-CoV Spike Protein RBD |
|||
| MBS515782-005mg | MyBiosource | 0.05mg | EUR 365 |
SARS-CoV Spike Protein RBD |
|||
| MBS515782-01mg | MyBiosource | 0.1mg | EUR 495 |
SARS-CoV Spike Protein RBD |
|||
| MBS515782-5x01mg | MyBiosource | 5x0.1mg | EUR 1965 |
Anti SARS-Cov-2 Spike (RBD) Mab |
|||
| 112057 | Antibody Research Corporation | 100 µg | Ask for price |
SARS-CoV-2 Spike RBD Mouse mAb |
|||
| A23771 | Abclonal | 100μL | EUR 343.62 |
|
Description: A synthetic peptide corresponding to a sequence within amino acids 600-700 of human RSK2 / RPS6KA3 (P51812). |
|||
SARS-CoV-2 Spike RBD Mouse mAb |
|||
| E45M22081N | EnoGene | 50 ul | EUR 346.5 |
SARS-CoV/SARS-CoV-2 Spike RBD Antibody, Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8119487-002mL | MyBiosource | 0.02mL | EUR 175 |
SARS-CoV/SARS-CoV-2 Spike RBD Antibody, Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8119487-01mL | MyBiosource | 0.1mL | EUR 365 |
SARS-CoV/SARS-CoV-2 Spike RBD Antibody, Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8119487-5x01mL | MyBiosource | 5x0.1mL | EUR 1500 |
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody, Mouse PAb |
|||
| MBS8119550-002mL | MyBiosource | 0.02mL | EUR 325 |
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody, Mouse PAb |
|||
| MBS8119550-01mL | MyBiosource | 0.1mL | EUR 580 |
SARS-CoV-2 (2019-nCoV) Spike RBD Antibody, Mouse PAb |
|||
| MBS8119550-5x01mL | MyBiosource | 5x0.1mL | EUR 2460 |
SARS-CoV-2 Spike RBD Nanobody [A1] |
|||
| A74271 | EpiGentek | 50 µl | EUR 299 |
SARS-CoV-2 Spike RBD (T478K) Protein |
|||
| PH0169M49 | Leading Biology | 100 µg | Ask for price |
SARS-CoV-2 Spike RBD 319-335 peptide |
|||
| SB086 | Smartox Biotechnology | 1 | EUR 111.03 |
|
Description: SARS-CoV-2 Spike RBD 319-335 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 319-335 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 319-335 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 336-347 peptide |
|||
| SB087 | Smartox Biotechnology | 1 | EUR 99.34 |
|
Description: SARS-CoV-2 Spike RBD 336-347 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 336-347 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 336-347 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 348-357 peptide |
|||
| SB088 | Smartox Biotechnology | 1 | EUR 93.5 |
|
Description: SARS-CoV-2 Spike RBD 348-357 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 348-357 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 348-357 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 352-365 peptide |
|||
| SB089 | Smartox Biotechnology | 1 | EUR 105.19 |
|
Description: SARS-CoV-2 Spike RBD 352-365 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 352-365 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 352-365 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 371-394 peptide |
|||
| SB090 | Smartox Biotechnology | 1 | EUR 128.56 |
|
Description: SARS-CoV-2 Spike RBD 371-394 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 371-394 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 371-394 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 395-430 peptide |
|||
| SB091 | Smartox Biotechnology | 1 | EUR 151.94 |
|
Description: SARS-CoV-2 Spike RBD 395-430 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 395-430 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 395-430 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 513-520 peptide |
|||
| SB096 | Smartox Biotechnology | 1 | EUR 93.5 |
|
Description: SARS-CoV-2 Spike RBD 513-520 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 513-520 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 513-520 (Biotin-LC) peptide |
|||
SARS-CoV-2 Spike RBD 523-541 peptide |
|||
| SB097 | Smartox Biotechnology | 1 | EUR 151.94 |
|
Description: SARS-CoV-2 Spike RBD 523-541 peptide is an epitope of interest of the SARS-CoV-2 Spike S glycoprotein Receptor-Binding Domain (RBD). SARS-CoV-2 Spike RBD 523-541 peptide is useful for vaccine development and for structure-activity relationship studiesSARS-CoV-2 Spike (S) glycoproteinSpike (S) glycoprotein corresponds to one of the leading targets for COVID-19 disease. Present on the surface of Sars-CoV-2 virus, Spike S protein is a class I fusion protein that allows the virus to enter host cells.With a 1 273 aa length, Spike protein has 2 subunits : S1 contains the receptor-binding domain RBD and S2 induces the fusion of the viral envelop with the cellular membrane. SARS-CoV-2 Spike RBD: The receptor-binding domain in SARS-CoV-2 Spike protein allows binding to the Angiotensin-Converting Enzyme receptor 2 (ACE2 receptor) which mediates the viral entry. SB-PEPTIDE also offers SARS-CoV-2 Spike RBD 523-541 (Biotin-LC) peptide |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
|||
| 9087-biotin-002mg | ProSci | 0.02 mg | EUR 229.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
|||
| 9087-biotin-01mg | ProSci | 0.1 mg | EUR 594.26 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
|||
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
|||
| MBS154680-01mg | MyBiosource | 0.1mg | EUR 500 |
SARS-CoV-2 (COVID-19) Spike RBD Antibody (biotin) |
|||
| MBS154680-5x01mg | MyBiosource | 5x0.1mg | EUR 2230 |
SARS-CoV Spike/RBD Protein (RBD, His Tag) |
|||
| E45O54856I2-100 | EnoGene | 100 ug | EUR 1574.9 |
SARS-CoV Spike/RBD Protein (RBD, mFc Tag) |
|||
| E45O54992M4-100 | EnoGene | 100 ug | EUR 1574.9 |
SARS-CoV Spike/RBD Protein (RBD, rFc Tag) |
|||
| E45O54454I4-100 | EnoGene | 100 ug | EUR 1574.9 |
SARS-CoV Spike/RBD Protein (RBD, mFc Tag) |
|||
| MBS8122158-01mg | MyBiosource | 0.1mg | EUR 560 |
SARS-CoV Spike/RBD Protein (RBD, mFc Tag) |
|||
| MBS8122158-5x01mg | MyBiosource | 5x0.1mg | EUR 2370 |
SARS-CoV Spike/RBD Protein (RBD, His Tag) |
|||
| MBS8122161-01mg | MyBiosource | 0.1mg | EUR 560 |
SARS-CoV Spike/RBD Protein (RBD, His Tag) |
|||
| MBS8122161-5x01mg | MyBiosource | 5x0.1mg | EUR 2370 |
SARS-CoV Spike/RBD Protein (RBD, rFc Tag) |
|||
| MBS8122162-01mg | MyBiosource | 0.1mg | EUR 560 |
SARS-CoV Spike/RBD Protein (RBD, rFc Tag) |
|||
| MBS8122162-5x01mg | MyBiosource | 5x0.1mg | EUR 2370 |
SARS-CoV Spike/RBD Protein (RBD, rFc Tag) |
|||
| PO54454I4 | Leading Biology | 100 µg | Ask for price |
SARS-CoV Spike/RBD Protein (RBD, His Tag) |
|||
| PO54856I2 | Leading Biology | 100 µg | Ask for price |
SARS-CoV Spike/RBD Protein (RBD, mFc Tag) |
|||
| PO54992M4 | Leading Biology | 100 µg | Ask for price |
SARS-CoV Spike RBD Rabbit mAb |
|||
| A22368 | Abclonal | 200μL | EUR 343.62 |
|
Description: A synthetic peptide corresponding to a sequence within amino acids 50-150 of human MyD88 (NP_002459.3). |
|||
SARS-CoV Spike RBD Rabbit mAb |
|||
| A21181 | Abclonal | 1000μL | EUR 828.95 |
|
Description: Recombinant fusion protein containing a sequence corresponding to amino acids 161-304 of human Myelin Basic Protein (P02686). |
|||
SARS-CoV-2 Spike RBD polyclonal antibody |
|||
| BS80241 | Bioworld Biotech | 50ul | EUR 358 |
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
|||
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|||
| EGVR1002 | EnoGene | 2019-nCoV-rabbit-polyclonal-antibody | EUR 276.5 |
|
Description: 2019-nCoV rabbit polyclonal antibody |
|||
Recombinant SARS-Cov-2 Spike RBD Protein |
|||
| MBS355914-1mg | MyBiosource | 1mg | EUR 1260 |
Recombinant SARS-Cov-2 Spike RBD Protein |
|||
| MBS355914-5x1mg | MyBiosource | 5x1mg | EUR 5360 |
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|||
| MBS8574970-01mg | MyBiosource | 0.1mg | EUR 475 |
SARS-CoV-2 Spike RBD Polyclonal Antibody |
|||
| MBS8574970-5x01mg | MyBiosource | 5x0.1mg | EUR 1985 |
Recombinant SARS-COV-2 Spike RBD Protein |
|||
| RP02325 | Abclonal | 500μg | EUR 265.69 |
Recombinant SARS-COV-2 Spike RBD Protein |
|||
| RP02332 | Abclonal | 500μg | EUR 244.43 |
Recombinant SARS-CoV-2 Spike RBD Protein |
|||
| RP01258 | Abclonal | 100μg | EUR 109.82 |
Recombinant SARS-CoV-2 Spike RBD Protein |
|||
| RP01271 | Abclonal | 100μg | EUR 113.36 |
Recombinant SARS-CoV-2 Spike RBD Protein |
|||
| RP01278 | Abclonal | 100μg | EUR 201.92 |
Recombinant SARS-CoV-2 Spike RBD Protein |
|||
| RP01282 | Abclonal | 100μg | EUR 1399.29 |
SARS-CoV-2 Spike RBD , Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8124174-01mg | MyBiosource | 0.1mg | EUR 520 |
SARS-CoV-2 Spike RBD , Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8124174-5x01mg | MyBiosource | 5x0.1mg | EUR 2185 |
SARS-CoV-2 Spike RBD, mammalian recombinant |
|||
| MBS664120-01mg | MyBiosource | 0.1mg | EUR 595 |
SARS-CoV-2 Spike RBD, mammalian recombinant |
|||
| MBS664120-05mg | MyBiosource | 0.5mg | EUR 1025 |
SARS-CoV-2 Spike RBD, mammalian recombinant |
|||
| MBS664120-1mg | MyBiosource | 1mg | EUR 1410 |
SARS-CoV-2 Spike RBD, mammalian recombinant |
|||
| MBS664120-5x1mg | MyBiosource | 5x1mg | EUR 5995 |
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
| 10-100 | ProSci | 0.1 mg | EUR 651.3 |
|
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensin-converting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
| 10-117 | ProSci | 0.1 mg | EUR 752.1 |
|
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
| 10-204 | ProSci | 0.1 mg | EUR 651.3 |
|
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
| 10-206 | ProSci | 0.1 mg | EUR 651.3 |
|
Description: The spike protein (S) of coronavirus (CoV) attaches the virus to its cellular receptor, angiotensinconverting enzyme 2 (ACE2). A defined receptor-binding domain (RBD) on S mediates this interaction.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
|||
SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
| 10-303 | ProSci | 0.1 mg | EUR 632.4 |
|
Description: SARS-CoV-2 (COVID-19) Spike RBD Recombinant Protein |
|||
SARS-CoV/SARS-CoV-2 Spike RBD Antibody(HRP), Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8124150-01mg | MyBiosource | 0.1mg | EUR 520 |
SARS-CoV/SARS-CoV-2 Spike RBD Antibody(HRP), Rabbit PAb, Antigen Affinity Purified |
|||
| MBS8124150-5x01mg | MyBiosource | 5x0.1mg | EUR 2185 |
SARS-CoV-2 Spike RBD, mFc/His tag |
|||
| MBS4758750-01mL | MyBiosource | 0.1mL | EUR 450 |
SARS-CoV-2 Spike RBD, mFc/His tag |
|||
| MBS4758750-5x01mL | MyBiosource | 5x0.1mL | EUR 1540 |
SARS-CoV-2 Spike Protein RBD Antibody |
|||
| abx376526-96tests | Abbexa | 96 tests | EUR 243.75 |
SARS-CoV-2 Spike Protein RBD Antibody |
|||
| abx229486-100g | Abbexa | 100 µg | EUR 350 |
SARS-CoV Spike RBD polyclonal antibody |
|||
| BS80270 | Bioworld Biotech | 50ul | EUR 358 |
|
Description: 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2 |
|||
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201273-001mg | MyBiosource | 0.01mg | EUR 265 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201273-002mg | MyBiosource | 0.02mg | EUR 360 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201273-005mg | MyBiosource | 0.05mg | EUR 450 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201273-01mg | MyBiosource | 0.1mg | EUR 670 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201273-025mg | MyBiosource | 0.25mg | EUR 1075 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201279-001mg | MyBiosource | 0.01mg | EUR 230 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201279-002mg | MyBiosource | 0.02mg | EUR 300 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201279-005mg | MyBiosource | 0.05mg | EUR 350 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201279-01mg | MyBiosource | 0.1mg | EUR 510 |
Recombinant SARS-CoV Spike RBD protein |
|||
| MBS201279-025mg | MyBiosource | 0.25mg | EUR 805 |
Recombinant SARS-CoV Spike RBD Protein |
|||
| RP02481 | Abclonal | 500μg | EUR 244.43 |
Recombinant SARS-CoV Spike RBD Protein |
|||
| RP01299 | Abclonal | 100μg | EUR 41.8 |
Recombinant SARS-CoV Spike RBD Protein |
|||
| RP01304 | Abclonal | 500μg | EUR 162.96 |
SARS-CoV-2 Spike RBD Variant B.1.1.248 |
|||
| MBS335862-01mg | MyBiosource | 0.1mg | EUR 575 |
SARS-CoV-2 Spike RBD Variant B.1.1.248 |
|||
| MBS335862-5x01mg | MyBiosource | 5x0.1mg | EUR 2570 |
SARS-COV/SARS-COV-2 Spike RBD Polyclonal Antibody(2019-nCoV) |
|||
| MBS2563840-005mL | MyBiosource | 0.05mL | EUR 275 |
SARS-COV/SARS-COV-2 Spike RBD Polyclonal Antibody(2019-nCoV) |
|||
| MBS2563840-01mL | MyBiosource | 0.1mL | EUR 415 |
